DYN
Q4 2026 EPS Estimate
$-0.86
Nov 4, 2026
FY2030E EPS$0.84

Analyst Sentiment

Wall St. Consensus
Buy
14 analysts·Moderate coverage
73
Score
12 Buy (86%)2 Hold (14%)0 Sell (0%)
Rating Breakdown
Strong Buy
17%
Buy
1179%
Hold
214%
Sell
00%
Strong Sell
00%

Analyst ratings reflect Wall Street opinion, not guarantees. Historical accuracy varies by firm and sector.

Price Target Expectations

Bear
$24.00
-6.6%
Consensus
$35.50
+38.1%
Bull
$45.00
+75.1%
12-Month Target Range14 analysts
$24.00$35.50$45.00
Current $25.70Consensus
Current Price
$25.70
Upside to Consensus
$9.80

Price targets are 12-month analyst forecasts. Actual results depend on earnings, market conditions, and sector trends.

Earnings & Revenue Estimates

Forward Growth Estimates (YoY)
FY2027
Rev+5023.68%
EPS
FY2028
Rev+465.71%
EPS
FY2029
Rev+156.98%
EPS
Raw consensus estimates (low / average / high) from covering analysts.
Annual
MetricFY2026EFY2027EFY2028EFY2029EFY2030E
Revenue Avg$995,727$51M$289M$742M$1.25B
Low$340,717$11M$102M$254M$429M
High$3M$108M$774M$1.92B$3.24B
EBITDA Avg
Low
High
EBIT Avg
Low
High
Net Income Avg$-455M$-432M$-471M$-129M$108M
Low$-533M$-563M$-791M$-394M$16M
High$-376M$-300M$5M$-19M$332M
EPS Avg$-3.46$-3.26$-2.49$-1.00$0.84
Low$-4.15$-4.38$-6.16$-3.07$0.12
High$-2.93$-2.34$0.04$-0.15$2.58
Analysts (Rev / EPS)9 / 1011 / 1210 / 105 / 45 / 4
Quarterly
MetricQ3 2026Q4 2026Q1 2027Q2 2027Q3 2027Q4 2027
Revenue Avg$3M$8M$12M$16M
Low$3M$8M$12M$16M
High$3M$8M$12M$16M
EBITDA Avg
Low
High
EBIT Avg
Low
High
Net Income Avg$-143M$-142M$-142M$-145M$-144M$-142M
Low$-170M$-166M$-142M$-145M$-144M$-142M
High$-122M$-112M$-142M$-145M$-144M$-142M
EPS Avg$-0.86$-0.86$-0.86$-0.87$-0.87$-0.86
Low$-1.03$-1.00$-0.86$-0.87$-0.87$-0.86
High$-0.74$-0.68$-0.86$-0.87$-0.87$-0.86
Analysts (Rev / EPS) / 10 / 101 / 81 / 81 / 81 / 8

Earnings Surprises

Recent Analyst Actions

Jul 31, 2026Morgan Stanley
Dyne Therapeutics price target lowered to $45 from $47 at Morgan Stanley
Target:$45.00
+82.6%from $24.64
May 15, 2026Evercore ISI
Dyne Therapeutics price target lowered to $33 from $34 at Evercore ISI
Target:$33.00
+85.5%from $17.79
May 13, 2026Bernstein
Dyne Therapeutics price target raised to $24 from $23 at Bernstein
Target:$24.00
+30.6%from $18.37
Mar 2, 2026Chardan Capital
Chardan Reiterates Buy Rating on Dyne Therapeutics (DYN)
Target:$38.00
+135.3%from $16.15
Mar 2, 2026Morgan Stanley
Dyne Therapeutics (DYN) PT Lowered to $47 at Morgan Stanley
Target:$47.00
+199.7%from $15.68
Dec 15, 2025Evercore ISI
Dyne Therapeutics price target lowered to $36 from $38 at Evercore ISI
Target:$36.00
+84.5%from $19.51
Dec 11, 2025Stifel Nicolaus
Dyne Therapeutics price target raised to $39 from $36 at Stifel
Target:$39.00
+98.1%from $19.69
Dec 10, 2025Oppenheimer
Dyne Therapeutics upgraded to Outperform from Perform at Oppenheimer
Target:$40.00
+116.9%from $18.44
Dec 9, 2025Tudor Pickering
Dyne Therapeutics (DYN) PT Raised to $23 at Bernstein SocGen Group
Target:$23.00
+20.5%from $19.09
Dec 9, 2025Bernstein
Dyne Therapeutics price target raised to $23 from $21 at Bernstein
Target:$23.00
+3.6%from $22.20
Dec 8, 2025Morgan Stanley
Dyne Therapeutics (DYN) PT Raised to $50 at Morgan Stanley
Target:$50.00
+125.2%from $22.20
Dec 8, 2025Robert W. Baird
Baird Reiterates Outperform Rating on Dyne Therapeutics (DYN)
Target:$30.00
+30.3%from $23.02
Dec 8, 2025H.C. Wainwright
Dyne Therapeutics price target raised to $60 from $46 at H.C. Wainwright
Target:$60.00
+155.1%from $23.52
Dec 8, 2025Raymond James
Dyne Therapeutics (DYN) PT Raised to $40 at Raymond James
Target:$40.00
+71.1%from $23.38
Nov 25, 2025Bernstein
Dyne Therapeutics price target raised to $21 from $12 at Bernstein
Target:$21.00
-3.1%from $21.67
Nov 6, 2025Evercore ISI
Dyne Therapeutics price target lowered to $38 from $41 at Evercore ISI
Target:$38.00
+102.2%from $18.79
Oct 10, 2025Oppenheimer
Dyne Therapeutics downgraded to Perform at Oppenheimer following additional data
Target:$13.00
-11.4%from $14.68
Aug 25, 2025Raymond James
Dyne Therapeutics upgraded to Strong Buy from Outperform at Raymond James
Target:$35.00
+169.2%from $13.00
Jun 2, 2025Oppenheimer
Dyne Therapeutics assumed with an Outperform at Oppenheimer
Target:$34.00
+167.7%from $12.70
Feb 28, 2025UBS
Dyne Therapeutics price target lowered to $48 from $53 at Piper Sandler
Target:$48.00
+252.7%from $13.61
Feb 28, 2025H.C. Wainwright
Dyne Therapeutics price target lowered to $46 from $55 at H.C. Wainwright
Target:$46.00
+238.0%from $13.61
Aug 14, 2024Morgan Stanley
Dyne Therapeutics price target raised to $52 from $48 at Morgan Stanley
Target:$52.00
+19.2%from $43.64
Aug 13, 2024Piper Sandler
Dyne Therapeutics price target raised to $53 from $43 at Piper Sandler
Target:$53.00
+23.1%from $43.07
Jun 24, 2024Jefferies
Jefferies Reiterates Buy Rating on Dyne Therapeutics (DYN)
Target:$42.00
+16.9%from $35.94
Jun 17, 2024Oppenheimer
Oppenheimer Reiterates Outperform Rating on Dyne Therapeutics (DYN)
Target:$55.00
+71.1%from $32.15
Data is provided for informational purposes only and does not constitute investment advice. Past performance is not indicative of future results.